Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Third-quarter FDA submission is expected for use of implantable cardiac defibrillators in treating nonsustained but inducible ventricular tachycardia. Data from the Multicenter Unsustained Tachycardia Trial (MUSTT) will support the filing, the firm says. Preliminary results reported March 8 at the American College of Cardiology conference from the 2,200-patient trial sponsored by NIH show that among patients whose therapy was guided by electrophysiological testing, ICD patients had "risk of arrhythmic death reduced by greater than 50%" compared to the group receiving anti-arrhythmic drugs or other conventional therapy," according to a same-day Medtronic release
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.